– UK, Reading – Provexis plc (AIM:PXS), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow heart-health functional food ingredient, is delighted to announce that Frédéric Boned has been appointed to the position of Non-executive Director with immediate effect.
Frédéric Boned, a Swiss and French national, is EMEA Vice President of DSM’s Human Nutrition & Health business, a part of DSM Nutritional Products.
Frédéric brings a wealth of sales and marketing knowledge and expertise to the Company from a diverse working background. Frédéric has a chemical engineering degree from the Engineering School in Geneva, and an EMBA from the Business School of Lausanne. Frédéric first joined DSM in 2012, holding a variety of senior roles in DSM’s Personal Care & Aroma Ingredients business including Director of Personal Care EMEA and Senior Director of Global Marketing and Innovation. Prior to DSM, Frédéric worked in the Flavour and Fragrance industries, holding several sales and marketing positions for over ten years at Givaudan.
Dawson Buck, Chairman of Provexis, commented: ‘I am delighted to welcome Frédéric Boned to Provexis as a Non-executive Director. Frédéric’s proven sales and marketing knowledge and expertise will help to drive Provexis and its core Fruitflow product forward, and we look forward to Frédéric’s input as we progress the company’s commercialisation strategy for its Fruitflow + Omega-3 dietary supplement product.
Frédéric’s appointment reflects the continued strength of the long term relationship between Provexis and DSM, and the shared interest of both companies in seeking to maximise the commercial returns that can be achieved from Fruitflow.’
Provexis has a long-term Alliance Agreement with DSM Nutritional Products for its core Fruitflow® heart health ingredient, which has seen the Company collaborate with DSM to develop Fruitflow in all major global markets through sales as an ingredient to brand owners in the food, beverage and dietary supplement categories. DSM Nutritional Products is a subsidiary of Royal DSM NV, a company listed on Euronext Amsterdam with a current market capitalisation in excess of €15bn.
DSM Venturing BV, the corporate venturing unit of Royal DSM NV, remains the Company’s largest shareholder with an interest representing 7.6 per cent of the Company’s issued ordinary share capital.
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow heart-health functional food ingredient.
In May 2009, the Company’s Fruitflow technology was the first to be substantiated by the European Food Safety Authority (‘EFSA’) under the new Article 13(5) for proprietary and emerging science. In December 2009 the European Commission authorised the health claim ‘Helps maintain normal platelet aggregation, which contributes to healthy blood flow’, which was the first wording to be authorised under Article 13(5).
In June 2010 it was announced that the Company had entered into a long-term Alliance Agreement with DSM Nutritional Products to commercialise Fruitflow, and in June 2015 the Company confirmed it had agreed significantly enhanced financial terms for its Alliance Agreement with DSM for Fruitflow.
The Company’s Alliance partner DSM Nutritional Products has developed the market actively for the Company’s novel, patented Fruitflow heart-health ingredient in all global markets, with over 50 regional consumer healthcare brands now having been launched by direct customers of DSM, and with a number of further regional brands having been launched through DSM’s distributor channels.
An increasing number of further commercial projects have been initiated by DSM with prospective customers, including some prospective customers which are part of global businesses, with good prospects for these projects to be launched as consumer products. Interest in the technology exists in all major global markets.
For more information : http://www.provexis.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.